MN-CAPILLARY-TECH
15.3.2023 14:01:50 CET | Business Wire | Press release
Capillary Technologies, a customer loyalty SaaS platform, has been named a Leader in “The Forrester WaveTM: Loyalty Technology Solutions, Q1 2023” report. Capillary’s Loyalty+ has earned 5/5 for 13 of the 28 criteria evaluated by Forrester.
The report, authored by Mary Pilecki and Cole Walsh, says that brands continue to invest in loyalty programs and loyalty technology solutions to help them engage and retain consumers — who are cutting back on spending and looking for more deals in response to higher prices. And according to Forrester’s Marketing Survey, 2023, “53% of B2C marketing decision-makers plan to increase their spend on loyalty technology in 2023, and economic uncertainty and scrutiny of marketing budgets has renewed marketers’ focus on the profitability of their loyalty strategies.”
Naming Capillary as a leader, the report states, “Capillary Technologies excels with robust tech capabilities and AI-powered nudges. Capillary Technologies offers a commerce solution, a customer data platform (CDP), and a loyalty platform, and expanded its loyalty reach by acquiring Persuade — a customer experience (CX) technology company — in 2021. Since then, Capillary has enhanced capabilities in its Loyalty+ offering for global clients in APAC, EMEA, and NA.”
In a Wave evaluation where 12 of the most significant vendors were considered, Capillary was evaluated to be one of only three leaders. “For us, this Forrester citation firmly establishes Capillary as a front-runner in the Loyalty Solutions space globally. For more than a decade now, we’ve helped hundreds of large enterprises realize the power of technology in delivering highly efficient loyalty programs to achieve the desired business outcomes. The evaluation in The Forrester Wave as a Leader is, in our opinion, a validation for the hard work the team has put in relentlessly over the years in helping brand marketers achieve extraordinary results and achieve customer loyalty as an outcome,” says Sameer Garde, CEO of Capillary Technologies.
The report further goes on to state, “Loyalty+ outpaces many in this competitive set because of robust functionality and a flexible data model. It excels in both loyalty program management and marketing, as well as in creating actionable insights from both customer and business data. And the platform’s 'nudges' feature leverages AI/ML to give marketers prescriptive advice on everything from program optimization to campaign management.”
About Capillary Technologies: Founded in 2012, Capillary Technologies has a presence across the United States, India, Middle East, and Asia, in particular, Southeast Asia. Capillary Technologies offers end-to-end loyalty programs, a comprehensive view of consumers and unified, cross-channel strategies that deliver a real-time omnichannel, personalized, and consistent experience for customers. Powering a diversified product suite of end-to-end loyalty programs, across 30+ countries, Capillary Technologies works with 250+ brands as of October 30, 2021, including Asics, PUMA, Shell, Tata, Fossil, Hoya, Pantaloons, GKB Opticals, Indian Terrain, Fossil, Vishal Megamart and many more from verticals such as apparel, footwear, supermarkets, conglomerates, manufacturing and electronics, pharmacy and wellness, fine dining and QSR, luxury and jewelry, entertainment, oil and gas, travel and hospitality. With a massive reach of 875 million+ consumers and processing 1.97 billion+ transactions in Fiscal 2021, Capillary Technologies’ promoter i.e., Capillary Technologies International Pte. Ltd. has the backing of Swanland Investment ltd. (an affiliate of Warburg Pincus), Sequoia Capital India Growth Fund II Ltd., Avataar Ventures Partners I, and Filter Capital Fund I Ltd. For more information, visit www.capillarytech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005270/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom